Identification of Plasma Biomarkers from Rheumatoid Arthritis Patients Using an Optimized Sequential Window Acquisition of All THeoretical Mass Spectra (SWATH) Proteomics Workflow
-
Published:2023-10-16
Issue:4
Volume:11
Page:32
-
ISSN:2227-7382
-
Container-title:Proteomes
-
language:en
-
Short-container-title:Proteomes
Author:
Jin Liang1ORCID, Wang Fei1, Wang Xue1, Harvey Bohdan P.1, Bi Yingtao1, Hu Chenqi2, Cui Baoliang1, Darcy Anhdao T.1, Maull John W.1, Phillips Ben R.1, Kim Youngjae2, Jenkins Gary J.1, Sornasse Thierry R.1, Tian Yu1ORCID
Affiliation:
1. Research & Development, AbbVie, North Chicago, IL 60064, USA 2. DMPK, Takeda Development Center Americas Inc., Cambridge, MA 02142, USA
Abstract
Rheumatoid arthritis (RA) is a systemic autoimmune and inflammatory disease. Plasma biomarkers are critical for understanding disease mechanisms, treatment effects, and diagnosis. Mass spectrometry-based proteomics is a powerful tool for unbiased biomarker discovery. However, plasma proteomics is significantly hampered by signal interference from high-abundance proteins, low overall protein coverage, and high levels of missing data from data-dependent acquisition (DDA). To achieve quantitative proteomics analysis for plasma samples with a balance of throughput, performance, and cost, we developed a workflow incorporating plate-based high abundance protein depletion and sample preparation, comprehensive peptide spectral library building, and data-independent acquisition (DIA) SWATH mass spectrometry-based methodology. In this study, we analyzed plasma samples from both RA patients and healthy donors. The results showed that the new workflow performance exceeded that of the current state-of-the-art depletion-based plasma proteomic platforms in terms of both data quality and proteome coverage. Proteins from biological processes related to the activation of systemic inflammation, suppression of platelet function, and loss of muscle mass were enriched and differentially expressed in RA. Some plasma proteins, particularly acute-phase reactant proteins, showed great power to distinguish between RA patients and healthy donors. Moreover, protein isoforms in the plasma were also analyzed, providing even deeper proteome coverage. This workflow can serve as a basis for further application in discovering plasma biomarkers of other diseases.
Subject
Clinical Biochemistry,Molecular Biology,Biochemistry,Structural Biology
Reference89 articles.
1. Proteomics in Rheumatoid Arthritis Research;Park;Immune Netw.,2015 2. Importance of 14-3-3eta, Anti-CarP, and Anti-Sa in the Diagnosis of Seronegative Rheumatoid Arthritis;Salman;Turk. J. Méd. Sci.,2019 3. Use and Utility of Serologic Tests for Rheumatoid Arthritis in Primary Care;Tenstad;Dan. Méd. J.,2020 4. Gold, L., Ayers, D., Bertino, J., Bock, C., Bock, A., Brody, E.N., Carter, J., Dalby, A.B., Eaton, B.E., and Fitzwater, T. (2010). Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery. PLoS ONE, 5. 5. Assarsson, E., Lundberg, M., Holmquist, G., Björkesten, J., Thorsen, S.B., Ekman, D., Eriksson, A., Dickens, E.R., Ohlsson, S., and Edfeldt, G. (2014). Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability. PLoS ONE, 9.
|
|